Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 1,801–1,900 of 3,116
Impact of Anti‐obesity Medication Initiation and Duration on Weight Loss
Bailony, M. R., Espinoza, P. G., Yüksel, H., Kyeso, I. M., Khalili, R., & Haller, S. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70069 · Cited by 2
Gouda, P., Allyn, N., Belin, R. M., Borentain, M., Butler, J., Curtis, L. H., George, J. T., Hornik, C. P. V., Jackman, J. G., Jessup, M. L., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102713 · Cited by 2
Self-citationEligibility for Anti-Obesity Medications Among Medicare Beneficiaries with Overweight or Obesity
Chetty, A. K., Khunte, M., Chen, A. S., Jastreboff, A. M., Krumholz, H. M., & Lu, Y. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-09178-8 · Cited by 1
Shlomov, T., Nitzan, I., Pollack, R. M., Zloto, O., & Gur, Z. (2026) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2026.01.010 · Cited by 2
Zhu, D., & Herrington, W. G. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-02457-jc · Cited by 1
The merits of an integrated approach to obesity treatment and prevention
Pratsides, L. (2024) · BMJ · doi:10.1136/bmj.q822 · Cited by 1
Incretin Mimetics in Cancer and Cardiovascular Disease
Leong, D. P., Gong, S., Sattar, N. A., Narayan, V., Reizine, N. M., Gerstein, H. C., & Vellky, J. E. (2026) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.12.003 · Cited by 3
Beran, M., Ekstrom, H. L., Crain, A. L., Hooker, S. A., Chumba, L. N., Appana, D., Kromrey, K., Kunisetty, G., McKinney, Z. J., Pronk, N. P., et al. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.107830 · Cited by 1
Galante, D., Vecchia, G. L., Leone, A. M., et al. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf021 · Cited by 1
Survodutide for the Treatment of Obesity
Platz, E., Kaplan, L. M., le Roux, C. W., Wharton, S., Burger, S., Hussain, S. A., Brueckmann, M., Startseva, E., Fey, C., Kosiborod, M., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102780 · Cited by 3
Calculating cost per event avoided using a composite number needed to treat
Toliver, J. C., Wang, J., Bhavsar, J., & Sullivan, S. D. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2615606 · Cited by 1
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2312-0389 · Cited by 1
Micalo, L., Archie, M. M., Rowe, V. L., Adewale, A. P., Pham, N. V., Li, A., & Jimenez, J. C. (2026) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2026.102557 · Cited by 2
Semaglutide and delayed gastric emptying: case report and analysis of anesthetic implications
Fortis-Olmedo, L. L., Serna-Muñoz, R., Villaseñor, J. A. C., Farca, T. A., & Calva-Ruíz, D. S. (2025) · Colombian Journal of Anesthesiology · doi:10.5554/22562087.e1137 · Cited by 4
Gallo, G., & Volpe, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf299 · Cited by 1
Top studies of 2023 relevant to primary care
Thomas, B. S., Perry, D., Moe, S. S., et al. (2024) · Canadian Family Physician · doi:10.46747/cfp.7004245 · Cited by 1
Ruseva, A., Michalak, W., Fabricatore, A. N., Hartaigh, B. Ó., Zhao, Z., Wang, J., & Umashanker, D. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2591464 · Cited by 3
“Semaglutide 2.4 mg improves cardiometabolic risk factors such as blood pressure (BP), cholesterol, and glycated hemoglobin (HbA1c) levels among patients with overweight or obesity with and without cardiovascular disease 15,16 .”
InfluentialFrederiksen, K., Berger‐Fleishman, R., Jad, A., Mattar, S. G., & Shetye, B. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100232 · Cited by 2
“1a. Therapeutic options for obesity care. fraction and obstructive sleep apnea [22 – 24].”
The dominant driver paradigm of cardiometabolic care
Sevillano, J. H., Babagoli, M. A., Chen, Y., Liu, S. H., Mellacheruvu, P., Johnson, J. G., Ibáñez, B., Lorenzo, Ó., & Mechanick, J. I. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101389 · Cited by 2
“…the recent SELECT trial, a pharmacological intervention for weight reduction in patients with overweight/obesity with preexisting CVD was superior to placebo in reducing mortality from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months [18].”
InfluentialHu, D., Ruan, J., Liu, C., et al. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07994-3 · Cited by 1
A Metabolic Health Framework to Interpret Weight Gain Studies in People With HIV
Guaraldi, G., & Milić, J. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciae646 · Cited by 1
Oral semaglutide and reduction in major adverse cardiovascular events
Duell, P. B., & Maki, K. C. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.04.001 · Cited by 1
Posicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250615 · Cited by 5
Carlino, I., Franco, S. D., Colalillo, N., Bisogno, S., Gennari, L., & Palazzuoli, A. (2026) · Biomedicines · doi:10.3390/biomedicines14061289 · Cited by 1
“Beyond GLP-1RA-mediated metabolic effects, increasing attention has focused on sex-specific determinants of HFpEF and on the interaction between hormonal dysregulation and cardiometabolic remodeling [70,87,88].”
Obesity management medications for the surgeon
Harris, M., Mahdi, S., Fairfield, C. J., Brown, L. R., Wadley, M., & Miras, A. D. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103307 · Cited by 1
Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.61622/rbgo/2025rbgo200 · Cited by 2
Mitropoulou, P., Prokšelj, K., Janež, A., Gil, F. R., Verma, S., Jurić, I., Vida, V. L., Gatzoulis, M. Α., & Brida, M. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag067 · Cited by 3
Kokura, Y., Kishimori, T., Kato, T., Iwasaki, Y., Wada, A., Tani, A., Yamaji, R., Koike, J., Matsumoto, T., Yagi, T., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113404 · Cited by 1
Ghosal, S., & Ghosal, A. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100281 · Cited by 2
“Recent large-scale trials, such as SCALE, STEP, SURMOUNT, and SELECT, confirm their efficacy in reducing body weight and enhancing cardiometabolic outcomes [5 – 8].”
Spending Money, Saving Money We Don’t Got: The Cost of Obesity
Stone, J. A., & Johnson, A. P. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.11.016 · Cited by 1
Plotkin, M., Ivkovic, M., Smith, I., Rathor, N., Chowdhury, R., Hodkinson, A., & Kushner, R. F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70911 · Cited by 2
Self-citationBoos, C. J., Schofield, S. J., Maqsood, R., Bull, A. M. J., Fear, N. T., Cullinan, P., Kemp, H. I., Bennett, A. N., & Study, F. T. A. (2026) · PLoS ONE · doi:10.1371/journal.pone.0345019 · Cited by 1
“…inference has been strengthened by data from randomised studies in which interventions such as exercise and diet/medication (e.g., statins and GLP-1 agonists) have led to reductions in Hs-CRP and visceral fat and increased autonomic function (HRV) and improvement in cardiovascular outcomes [33–35].”
Androutsopoulou, V. A., Brecher, V., Xanthopoulos, A. V., Avgerinos, D. V., Athanasiou, T., & Magouliotis, D. E. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13070305 · Cited by 1
“The cardiovascular outcome trial era, launched by the LEADER trial in 2016 and culminating in the SELECT trial in 2023, established a consistent signal of major adverse cardiovascular event (MACE) reduction across GLP-1 RA agents, patient phenotypes, and levels of baseline cardiovascular risk [3].”
Younis, A., Henney, A. E., Riley, D. R. J., Anson, M., Zhao, S. S., Hernández, G., Malik, R. A., Su, L., Lip, G. Y. H., Cuthbertson, D. J., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113083 · Cited by 4
Saeed, Z. I., & Apovian, C. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01369-w · Cited by 2
“It is important to note that the between-group difference in MACE emerged early in SELECT before maxi - mum weight loss was achieved, suggesting that semaglutide induced physiologic changes may have mediated at least part of the CV benefit [ 33].”
InfluentialOut-of-Pocket Costs and Adherence to Semaglutide for Obesity Among Commercially Insured Adults
Shin, E., Kim, H., Lee, J., Hall, D. B., & Rajbhandari, J. (2026) · JAMA Health Forum · doi:10.1001/jamahealthforum.2026.3113 · Cited by 1
Murugadoss, K., Venkatakrishnan, A. J., & Soundararajan, V. (2026) · Preprints.org · doi:10.64898/2026.04.23.26351609 · Cited by 1
Ahlers, M. J., John, S., Bhatia, H. S., Le, V. T., & Taub, P. R. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101265 · Cited by 5
Dai, H., Lee, Y. A., Natalie, A., et al. (2025) · medRxiv · doi:10.1101/2025.11.10.25339912 · Cited by 1
“17 This is particularly important given the substantial growth in ED-related spending accounting for roughly 5% of annual US healthcare costs equating to approximately $80 billion.”
Obesity pandemic – searching for the most effective treatments
Kołakowska, K. (2024) · Biuletyn Głównej Biblioteki Lekarskiej · doi:10.2478/bgbl-2024-0028 · Cited by 2
Hasebe, M., Kamido, H., Su, C., Keidai, Y., Yabe, D., & Yoshiji, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70749 · Cited by 2
“Consistent with our previous meta-regression of GLP-1RA CVOTs in type 2 diabetes [7], we found no association between the magnitude of body weight lowering and HF risk reduction, even after adding SELECT to the trial set [29].”
Walton, S., Guirguis, E. H., Mack, K., & Assil, R. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf251 · Cited by 1
Ponnana, S. R., Zhang, T., Sirasapalli, S. K., Chen, Z., Dazard, J.-E., Surya, N., Shamsa, E. H., Sivanantham, K., Okyere, R., Neeland, I. J., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70515 · Cited by 1
Theodorakis, N., Kreouzi, M., & Nikolaou, M. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10506-1 · Cited by 3
Lee, Y. H., Kim, D. K., Kim, J. S., Jeong, S. J., Jeong, K. H., & Hwang, H. S. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1652372 · Cited by 2
“In addition, glucagon-like peptide-1 receptor agonists (GLP-1RAs) not only facilitate weight reduction but also confer renoprotective (36, 37), cardioprotective (38, 39), and anti-inflammatory effects (40).”
Shah, P. P., & Bhattacharya, R. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101418 · Cited by 2
“Semaglutide demonstrated significant reductions in major adverse cardiovascular events in SUSTAIN-6 and, more recently, in non-diabetic patients with established CVD in the SELECT trial [3,22,23].”
Zhuang, S., & Jin, Y. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf579 · Cited by 1
Zawadzki, M., & Karczewska‐Kupczewska, M. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/8388511 · Cited by 1
“Additional insights were provided by randomized clinical trials conducted in patients with obesity, such as the SELECT trial (semaglutide), which demonstrated reductions in CV risk factors and a 20% decrease in MACE compared with placebo in patients treated with GLP-1 RAs [17].”
Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk
Kafol, J., Jug, B., & Fras, Z. (2026) · Cells · doi:10.3390/cells15141293 · Cited by 1
“However, discontinuation due to adverse events was more frequent with semaglutide, largely reflecting gastrointestinal tolerability [90].”
Alves, G. A. M., Teranishi, M., Majumdar, R., Khan, F., Dodeja, M., Ortega, A. C. T. D. C. G., Acerboni, M., Arachchige, A. S. P. M., & James, F. (2026) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.70048 · Cited by 4
Overgaard, K. S., Mohamed, R. A., Andersen, T. R., Lambrechtsen, J., Egstrup, K., & Auscher, S. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02340-w · Cited by 3
Gestational Weight Gain and Pregnancy Outcomes After Semaglutide Exposure
Yu, Y., Li, X., Groth, S. W., Zaman, A., Chao, A. M., Phelan, S., Hollenbach, S. J., & Dreisbach, C. (2026) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000006325 · Cited by 2
Healthcare utilization associated with obesity management in Ontario, Canada
Wharton, S., Belloum, A., Luckevich, M., Kamran, E., Luguzis, A., Eberg, M., KUKASWADIA, A. A., Neish, C. S., Capucci, S., Varbo, A., et al. (2024) · Clinical Obesity · doi:10.1111/cob.12720 · Cited by 3
Cardiovascular effects of semaglutide: Multifaceted mechanisms of systemic organoprotection
Demidova, T. Y., Izmaylova, M. Y., & Alieva, M. A. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-2-06 · Cited by 1
Italy passes obesity law: an opportunity to prevent cardiovascular disease across Europe
Malavazos, A. E., Dubini, C., Meregalli, C., Boniardi, F., Scravaglieri, V., Castelvecchio, S., Menicanti, L., Nisoli, E., & Carruba, M. O. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag094 · Cited by 1
Guidelines for obesity clinic consultations in primary healthcare clinics
Kang, J., & Kim, K. K. (2024) · Journal of Korean Medical Association · doi:10.5124/jkma.2024.67.4.240 · Cited by 3
Gupta, P., & Pozzilli, P. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112434 · Cited by 1
Inzucchi, S. E., Ghani, R. A., Deanfield, J. E., Emerson, S. S., Engelmann, M. D. M., Hovingh, G. K., Jeppesen, O. K., Kellerer, M., Mandavya, K., Mann, J. F. E., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag290
Self-citationVelasco, M. Á. P., Trenas, A., Bernal-López, M. R., et al. (2024) · Revista Española de Cardiología · doi:10.1016/j.recesp.2023.12.017 · Cited by 1
Pedicino, D., & Volpe, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf277 · Cited by 1
Warden, B. A., Duell, P. B., Bucheit, J. D., & Purnell, J. Q. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.013 · Cited by 1
Shi, L., Li, D., & Li, Y. (2026) · Medical Review · doi:10.1515/mr-2025-0048 · Cited by 3
“…showed that, in patients with a history of CVD and overweight or obesity but without diabetes, subcutaneous injection of 2.4 mg sem-aglutide once weekly reduces the incidence of cardiovascular death, non-fatal myocardial infarction or nonfatal stroke after a median follow-up of 39.8 months [87].”
InfluentialSon, H., Hwang, I., Lee, S. W., & Kim, Y. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70505 · Cited by 2
“By mitigating this challenging side effect without necessitating the discontinuation of effective seizure therapy, GLP-1 RAs may contribute to long-term epilepsy management through improved treatment adherence, reduced cardiovascular risk, and enhanced patient quality of life [32, 33].”
Glucagon-like Peptide 1 Receptor Agonist Use in Hospital: A Multicentre Observational Study
Ray, P., Moggridge, J. A., Weisman, A., Tadrous, M., Drucker, D. J., Perkins, B. A., & FRALICK, M. (2024) · Canadian Journal of Diabetes · doi:10.1101/2024.08.01.24311352 · Cited by 1
Saraiva, J. F. K., Valério, C. M., Rached, F. H., van de Sande‐Lee, S., Rocha, V. Z., Valente, F., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250621 · Cited by 17
“Após 30 anos de seguimento, houve redução nas taxas de eventos CV (HR 0,74, IC 95% [0,59, 0,92]), morte CV (0,67, IC 95% [0,48, 0,94], p = 0,022), morte global (0,74, IC 95% [0,61, 0,89], p = 0,0015) e postergaram em até 4 anos o diagnóstico de diabetes.”
Golec, S., Vaidya, A., Pitt, B., & Jaffe, I. Z. (2026) · Circulation Research · doi:10.1161/circresaha.126.327593 · Cited by 2
Extrakranielle Karotisstenose: Prävalenz, Diagnostik und Therapie
Andrassy, M., Zeller, T., Langhoff, R., Rammos, C., Tiefenbacher, C., Dahm, J. B., Marx, N., & Korosoglou, G. (2025) · Die Kardiologie · doi:10.1007/s12181-025-00768-2 · Cited by 1
Incretin therapy for cardiovascular disease: opportunities, mechanistic gaps, and challenges
Raaschou-Pedersen, D. E. T., & Sattar, N. A. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf983 · Cited by 1
First study with positive cardiovascular outcome in obesity: Reflections on SELECT
Pan, Q., Fei, S., Xie, T., & Guo, L. (2024) · Aging Medicine · doi:10.1002/agm2.12300 · Cited by 1
Mortada, I., Lee, A. W., Quach, V., Rice, J. C., Mansour, S., Chatila, K., Shalaby, M., Blackwell, T. A., & Jneid, H. M. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.03.020 · Cited by 1
Abdelrahman, R. M., Musa, T. H., Arbab, I. A., Ahmed, E. O., Gasmallah, S. I., Jalal, M., Ahmed, W. R., & Fadul, K. H. (2026) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580261441498 · Cited by 2
Guía latinoamericana de recomendaciones al egreso de un síndrome coronario agudo
Ponte-Negretti, C. I., Zaidel, E. J., López-Santi, R., Múnera, A. G., Bryce, A., M, S. N., Espinoza, J., Gaibor, J. C., Valcárcel, Y., Antonio, C. D., et al. (2024) · Archivos de cardiología de México · doi:10.24875/acm.m24000096 · Cited by 6
Alkhezi, O. S., Alfehaid, L., Alanezi, A., Alotaibi, M., & Alshaya, O. A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1805015 · Cited by 2
van der Zande, H. J. P., Zemer, A., Vrieling, F., Smeehuijzen, L., Attema, B. J., Muallem, H., Jansen, J., van der Linden, A., Prass, S., Wessels, D. W. R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.27.661006 · Cited by 2
GLP-1-RA – „New kid on the block“ in der Nephrologie?
Kraft, L., Schanz, M., & Latus, J. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2420-6176 · Cited by 1
Skalsky, K., Romi, M., Shiyovich, A., et al. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12040133 · Cited by 1
Khokhar, M., Yadav, D., & Sharma, P. (2026) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-026-01417-5 · Cited by 1
“GLP-1R expression in renal proximal tubular cells mediates natriuresis, reduced glomerular hyperfiltration, and attenuated albuminuria—effects confirmed in both the FLOW [ 8] and SELECT [1] trials.”
AGA Institute Quality Indicators for Obesity Medication Use in Practice
Newberry, C. A., Peng, F. B., Lynch, K. L., Sheth, S. G., Pickett‐Blakely, O., & Maratt, J. K. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.08.006 · Cited by 1
Paceana, M.-A., Mititelu-Tarțău, L., Boboc, I. K. Ş., Oancea, C. N., Berbecaru-Iovan, A., Foia, C. I., Tartau, C. G., & Bogdán, M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050620 · Cited by 1
“Lincoff et al. [87] concluded that semaglutide lowered the risk of non-fatal stroke and non-fatal myocardial infarction as well as the risk of death from cardiovascular causes in patients with pre-existing CVD who were overweight or obese.”
Zhang, J., Wang, C., Wang, J., Gu, W., Wang, H., Zhu, H., Ma, X., & Shi, Z. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-05664-9 · Cited by 1
Glucagon-Like Peptide-1 Is Prognostic of Mortality in Acute Respiratory Failure
Hansell, C. E., Aneis, H., Kitsios, G. D., Bain, W., Zhao, Y., Suber, T. L., Evankovich, J. W., Sharma, L., Ramakrishnan, S. K., Prendergast, N. T., et al. (2025) · Critical Care Explorations · doi:10.1097/cce.0000000000001247 · Cited by 4
Nicolau, J., Pujol, A., Gil, A., & Anesto, J. B. (2024) · Nutrición Hospitalaria · doi:10.20960/nh.05244 · Cited by 8
The Latest topics of Standards of Care in Diabetes 2025: Focusing on GLP-1RA
Bando, H., Wood, M., & Ebe, K. (2024) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2024/asjbccr.6386 · Cited by 1
Roddy, K. L., Greenwald, M. R., Hollman, N., Dorand, M. F., & Richards, J. R. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100199 · Cited by 4
Review of the top 5 cardiology studies of 2023–24
Barry, A. R., Boswell, R., Babadagli, H. E., Chen, J. W., Cowley, E. C., Eberhardt, T. E., & May, T. A. (2025) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635251339445 · Cited by 1
Semaglutide in non-diabetic patients with Fabry disease
Riccio, E., Capuano, I., & Pisani, A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf088 · Cited by 1
Selvan, N. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20260443 · Cited by 1
Lee, J. M., Kim, Y., Lee, S. Y., Kwon, W., Hwang, D., Chon, M. K., Joh, H. S., Lee, S. H., Lee, K. Y., Seo, Y. H., et al. (2026) · Korean Circulation Journal · doi:10.4070/kcj.2026.0191 · Cited by 1
“GLP-1 RAs significantly reduce major cardiovascular events in patients with obesity or overweight without type 2 diabetes 41) ; however, injectable administration limits broad implementation.”
Derkach, K. V., Basova, N. E., & Shpakov, A. O. (2025) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20250517 · Cited by 1
Silva, J. P. M. R. J., Nogueira, B., Sartori, D. L., da Silva, J. A. R., Sciota, L. B. A., Bisneto, O. I. D. M., & Gomes, W. F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71051 · Cited by 2
“These agents are independently associated with cardiovascular benefit, which may attenuate observable differences and reduce the likelihood of detecting incremental effects [8–12].”
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1445 · Cited by 1
Mann, J. F. E., Badve, S. V., Baeres, F. M. M., Belmar, N., Brown‐Frandsen, K., Buse, J. B., Colhoun, H. M., Deanfield, J. E., Engelmann, M. D. M., Hovingh, G. K., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00134-8 · Cited by 5
Self-citationTroshina, E. A., Suplotova, L. A., Dzgoeva, F. K., Ekusheva, E. V., Vyuchnova, E. S., Okovityi, S. V., Bakulin, I. G., Бакулина, Н. В., Karonova, T. L., Vagapova, G. R., et al. (2026) · Problems of Endocrinology · doi:10.14341/probl13737 · Cited by 1
Liuzzo, G., & Patrono, C. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf420 · Cited by 1
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
Kim, M. S., Shim, I., Kim, B., Do, R., Park, W.-Y., Khera, A. V., Natarajan, P., Ellinor, P. T., Fahed, A. C., & Won, H.-H. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101509 · Cited by 1
“With the recent introduction of glucagon-like peptide 1 (GLP-1) agonists as powerful weight loss medications that can even reduce major adverse cardiovascular outcomes by 20 %, [5] accurate identification of PLwO is more important than ever.”
Assessing the causal relationship between obesity and hypothyroidism using Mendelian randomization
Li, X., Li, H., Hong, T., Li, Z., & Wang, Z. (2024) · Journal of Investigative Medicine · doi:10.1177/10815589241257214 · Cited by 4
Yu, Z., Gu, B., Zhang, J., Jin, W., Wan, H., & Jin, W. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1721311 · Cited by 3
Adipositastherapie in Deutschland – quo vadis?
Hauner, H. (2024) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2240-9125 · Cited by 1
Cornelio, C. K., Cowart, K., Perkins, J. B., Alomar, M., Pineda-Gayoso, R., Miranda, A. C., Phan, A. T., & White, R. T. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70130 · Cited by 5
“Cardiovascular benefits of GLP-1 RAs have also been demonstrated in people with obesity and existing CVD, as well as in people with heart failure and obesity, independent of diabetes status [15, 16].”
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
